Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

Table 3 Intergroup and intragroup changes in cardiac function indexes

Indexes	Times	Sacubitril/valsartan (n = 106)	Valsartan (n = 106)	P
LVEF(%)^a	Baseline	45.11 ± 10.62	46.63 ± 11.14	0.311
LVEF(%)^a	16 weeks	56.00 ± 6.71^***	48.2 ± 7.59	< 0.001
LVEDD (mm)^a	Baseline	59.76 ± 9.32	58.57 ± 9.28	0.349
LVEDD (mm)^a	16 weeks	51.49 ± 6.33^***	52.57 ± 6.37^***	0.219
LAD (mm)^a	Baseline	46.02 ± 7.17	44.73 ± 7.21	0.192
LAD (mm)^a	16 weeks	40.39 ± 5.55^***	43.09 ± 5.75	0.001
NT-proBNP^b,c	Baseline	3607.10(1912.00,6388.30)	3006.50(1179.59,7190.28)	0.306
(pg/mL)	16 weeks	2134.50(821.25,4789.80)^***	1455.20(478.93,3400.50)^***	0.109

LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic diameter, LAD left atrial diameter, NT-proBNP N-terminal pro-brain natriuretic peptide
^a T test
^b Mann-Whitney U test
^c Wilcoxon rank sum test
Data with normal distribution is represented as mean ± standard deviation, median (quartile) is used to represent data with nonnormal distribution
^***P < 0.001 comapred with before treatment

ISSN: 1476-511X